

Vaccine Coverage Dutch National Influenza Prevention Program 2025: brief monitor


Claudia Laarman, Marianne Heins, Bart Knottnerus, Mariëtte Hooiveld

In the Netherlands, people who are at increased risk of complications from an influenza infection (flu), due to older age or a medical condition, are invited each year for influenza vaccination. In 2025, 54% of them were vaccinated.

In 2025, 54% (95%-confidence interval 47%-60%) of those invited for influenza vaccination at the GP were vaccinated which is comparable with 2024, when also 54% were vaccinated. However, the vaccine coverage has declined since 2021, when it was 58%. Presumably, more persons received their influenza vaccination due to the COVID-19 pandemic.

When comparing with previous years, changes in the criteria for a medical indication for influenza vaccination in 2022 should be taken into account. This is especially relevant for those under 60 years of age, as they are not invited automatically because of their age.

Figure 1 Trend in influenza vaccine coverage by age group and medical indication*, 2021-2025



* In 2022 changes were applied in the medical indications for influenza vaccination.

Table 1 Population size and influenza vaccine coverage within the target group, by age group and medical indication, 2025

Age group	Size (% of population)	Vaccine coverage (% of population)
0-59 years with medical indication*	7	27
60 years and older	31	58
Without medical indication	16	50
With medical indication	15	68
Entire target population	39	54

* Persons under age 60 only belong to the target population if they have a medical indication for influenza vaccination.

Table 2 Population size and influenza vaccine coverage by specific medical indication for vaccination, 2025

Medical indication	Size (% of target population)	Vaccine coverage (% of group)
Cardiovascular diseases	8	64
Pulmonary diseases	5.	57
Diabetes mellitus	6	59
Weakened immune system	4	52
Chronic renal failure	3	70
Respiratory disorders caused by neurological conditions	3	54
HIV	<1	42
Dementia	<1	68
Intellectual disability	<1	26
Morbid obesity (BMI ≥40)	<1	40

About the research

An influenza infection is relatively harmless for most people. However, in those who are vulnerable because of older age or medical conditions, influenza may cause serious complications. The World Health Organization (WHO) therefore recommends vaccination for vulnerable groups. Vaccination reduces both the risk of getting an influenza infection and the risk of complications in case of infection. The Dutch National Influenza Prevention Program, established in 1997, coordinates and implements the influenza vaccination program. Persons at risk for complications due to (the consequences of) influenza are invited by their general practitioner or institutional physician to receive influenza vaccination free of charge. The target group includes all people aged 60 years or older and those with certain medical conditions. Annual monitoring of vaccination uptake rates makes it possible to evaluate the number of people who are vaccinated (vaccine coverage) by the general practitioner each year. The monitor NPG 2025 was conducted by Nivel and commissioned by the National Institute for Public Health and the Environment (RIVM). Data from general practices participating in the Nivel Primary Care Database were used for the analysis. For more information (in Dutch), see: [Monitor Vaccinatiegraad Nationaal Programma Grieppreventie \(NPG\) 2025](#).

About Nivel

Nivel, Netherlands Institute for Health Services Research, is the national institute for health services research in the Netherlands. It is an independent organization which provides knowledge to improve healthcare in the Netherlands. We do this in conducting high-quality, reliable and independent scientific research on themes of major public interest. 'Research for better care' is our mission. Nivel publishes all its research publicly, as stipulated in the articles of association. Nivel has been certified ISO 9001 international quality standards. You can find this publication and all other Nivel publications at <https://www.nivel.nl/en/publications>.

Source citing

Information from this and all other Nivel publications (reports, factsheets, infographics and other downloadables) may be reproduced provided the source is acknowledged. The source disclosure components of Nivel publications are: Laarman C, Heins M, Kottnerus B, Hooiveld M. Vaccine Coverage Dutch National Influenza Prevention Program 2025: brief monitor. Utrecht: Nivel, 2026
